Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Ticker
CRBP right now
Market factors today
Unlock the full CRBP picture
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
CRBP stock facts
| Ticker symbol | CRBP |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $132.3M |
| CEO | Yuval Cohen |
| Employees | 36 |
| Headquarters | Norwood, MA, US |
| IPO date | 2014-10-27 |
| Website | www.corbuspharma.com |
What you can see for CRBP on Tickr
Live CRBP price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CRBP report.
Rankings
FAQ
What is the ticker symbol for Corbus Pharmaceuticals Holdings, Inc.?
The ticker symbol for Corbus Pharmaceuticals Holdings, Inc. is CRBP, listed on the NASDAQ.
What is CRBP?
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß…